Sign in or create an account to add this stock to your watchlist.
About Concert Pharmaceuticals (NASDAQ:CNCE)
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, which has completed the Phase 1 clinical trials for the treatment of patients with narcolepsy; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata. The company is also developing CTP-692, a selective deuterium-modified analog of the endogenous amino acid, D-serine, which is in preclinical studies for use in the treatment of patients with schizophrenia. It has strategic collaborations with Celgene Pharmaceuticals, Inc.; Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CNCE
CUSIPN/A
Phone781-860-0045
Debt
Debt-to-Equity RatioN/A
Current Ratio33.40
Quick Ratio33.40
Price-To-Earnings
Trailing P/E Ratio5.00
Forward P/E Ratio-9.23
P/E GrowthN/A
Sales & Book Value
Annual Sales$143.89 million
Price / Sales3.32
Cash Flow$4.2926 per share
Price / Cash4.75
Book Value$8.99 per share
Price / Book2.27
Profitability
EPS (Most Recent Fiscal Year)$4.08
Net Income$95.63 million
Net Margins67.71%
Return on Equity-23.57%
Return on Assets-20.68%
Miscellaneous
Employees64
Outstanding Shares23,400,000
Concert Pharmaceuticals (NASDAQ:CNCE) Frequently Asked Questions
What is Concert Pharmaceuticals' stock symbol?
Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."
How were Concert Pharmaceuticals' earnings last quarter?
Concert Pharmaceuticals (NASDAQ:CNCE) announced its earnings results on Thursday, May, 3rd. The biotechnology company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.39. The biotechnology company earned $10.48 million during the quarter. Concert Pharmaceuticals had a net margin of 67.71% and a negative return on equity of 23.57%. View Concert Pharmaceuticals' Earnings History.
What price target have analysts set for CNCE?
5 brokerages have issued 12-month price objectives for Concert Pharmaceuticals' shares. Their forecasts range from $25.00 to $34.00. On average, they expect Concert Pharmaceuticals' share price to reach $27.80 in the next year. View Analyst Ratings for Concert Pharmaceuticals.
What are Wall Street analysts saying about Concert Pharmaceuticals stock?
Here are some recent quotes from research analysts about Concert Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States. " (5/2/2018)
- 2. Mizuho analysts commented, "We don’t see a read-through from today’s news to the ultimate outcome of the IPR challenge. Based on how Concert has defended its patents historically and the impressive track record on IP protection front, we think it is likely they can win this challenge. PTAB Proceedings. In April 2017, Incyte filed an Inter Partes Review Petition (IPR) against Concert seeking to invalidate Concert’s U.S. Patent No. 9,249,149. Following this, in October 2017, the PTAB denied Incyte’s petition to institute the IPR. Today, the PTAB is granting Incyte’s motion for reconsideration. Oral arguments between the parties will be made in December followed by a PTAB decision, expected in April 2019. PLEASE REFER TO PAGE 3 OF THIS REPORT FOR IMPORTANT DISCLOSURE AND ANALYST CERTIFICATION INFORMATION. Mizuho Securities USA LLC does and seeks to do business with companies covered in its research reports." (4/10/2018)
Who are some of Concert Pharmaceuticals' key competitors?
Some companies that are related to Concert Pharmaceuticals include Madrigal Pharmaceuticals (MDGL), MyoKardia (MYOK), Aimmune Therapeutics (AIMT), Motif (MTFB), Phibro Animal Health (PAHC), Prestige Brands (PBH), Akorn (AKRX), G1 Therapeutics (GTHX), Cambrex (CBM), ARMO BioSciences (ARMO), PTC Therapeutics (PTCT), Innoviva (INVA), Zogenix (ZGNX), Radius Health (RDUS) and Pacira Pharmaceuticals (PCRX).
Who are Concert Pharmaceuticals' key executives?
Concert Pharmaceuticals' management team includes the folowing people:
- Mr. Richard H. Aldrich, Co-Founder & Chairman (Age 64)
- Dr. Roger D. Tung, Co-Founder, CEO, Pres & Director (Age 58)
- Ms. Nancy Stuart, Chief Operating Officer (Age 60)
- Dr. James V. Cassella, Chief Devel. Officer (Age 63)
- Mr. Marc A. Becker, Chief Financial Officer (Age 46)
Has Concert Pharmaceuticals been receiving favorable news coverage?
Media coverage about CNCE stock has been trending somewhat positive on Wednesday, according to Accern. The research firm identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Concert Pharmaceuticals earned a news impact score of 0.15 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 46.02 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.
Who are Concert Pharmaceuticals' major shareholders?
Concert Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include BVF Inc. IL (8.32%), BlackRock Inc. (6.82%), Dimensional Fund Advisors LP (3.15%), Northern Trust Corp (2.72%), Franklin Resources Inc. (2.47%) and Millennium Management LLC (1.85%). Company insiders that own Concert Pharmaceuticals stock include James V Cassella, Richard Aldrich, Ronald W Barrett, Ryan Lynch and Value Fund L P Biotechnology. View Institutional Ownership Trends for Concert Pharmaceuticals.
Which institutional investors are selling Concert Pharmaceuticals stock?
CNCE stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Lyon Street Capital LLC, BlackRock Inc., UBS Group AG, Senzar Asset Management LLC, Wells Fargo & Company MN, BVF Inc. IL and Franklin Resources Inc.. Company insiders that have sold Concert Pharmaceuticals company stock in the last year include James V Cassella, Richard Aldrich, Ronald W Barrett, Ryan Lynch and Value Fund L P Biotechnology. View Insider Buying and Selling for Concert Pharmaceuticals.
Which institutional investors are buying Concert Pharmaceuticals stock?
CNCE stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Matarin Capital Management LLC, Northern Trust Corp, Spark Investment Management LLC, Russell Investments Group Ltd., Thrivent Financial for Lutherans, ClariVest Asset Management LLC and Citadel Advisors LLC. View Insider Buying and Selling for Concert Pharmaceuticals.
How do I buy shares of Concert Pharmaceuticals?
Shares of CNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Concert Pharmaceuticals' stock price today?
One share of CNCE stock can currently be purchased for approximately $20.39.
How big of a company is Concert Pharmaceuticals?
Concert Pharmaceuticals has a market capitalization of $470.96 million and generates $143.89 million in revenue each year. The biotechnology company earns $95.63 million in net income (profit) each year or $4.08 on an earnings per share basis. Concert Pharmaceuticals employs 64 workers across the globe.
How can I contact Concert Pharmaceuticals?
Concert Pharmaceuticals' mailing address is 99 HAYDEN AVENUE SUITE 500, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-860-0045 or via email at [email protected]
MarketBeat Community Rating for Concert Pharmaceuticals (CNCE)
MarketBeat's community ratings are surveys of what our community members think about Concert Pharmaceuticals and other stocks. Vote "Outperform" if you believe CNCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
Concert Pharmaceuticals (NASDAQ:CNCE) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Concert Pharmaceuticals (NASDAQ CNCE) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.40%
Institutional Ownership Percentage: 74.41%
Concert Pharmaceuticals (NASDAQ CNCE) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/17/2018 | James V Cassella | Insider | Sell | 10,582 | $20.18 | $213,544.76 | 30,000 |  |
| 2/1/2018 | Richard Aldrich | Director | Sell | 11,946 | $20.89 | $249,551.94 | 286,975 | |
| 1/29/2018 | Richard Aldrich | Director | Sell | 18,054 | $20.63 | $372,454.02 | 286,975 | |
| 1/26/2018 | Richard Aldrich | Director | Sell | 5,000 | $20.46 | $102,300.00 | 286,975 | |
| 1/24/2018 | Richard Aldrich | Director | Sell | 30,000 | $19.68 | $590,400.00 | 286,975 | |
| 1/22/2018 | Richard Aldrich | Director | Sell | 10,000 | $19.55 | $195,500.00 | 286,975 | |
| 1/19/2018 | Richard Aldrich | Director | Sell | 30,000 | $19.35 | $580,500.00 | 286,975 | |
| 1/16/2018 | Richard Aldrich | Director | Sell | 31,236 | $19.14 | $597,857.04 | 286,975 | |
| 12/19/2017 | Value Fund L P Biotechnology | Insider | Sell | 1,282,856 | $26.65 | $34,188,112.40 | | |
| 12/4/2017 | Ronald W Barrett | Director | Sell | 14,156 | $24.70 | $349,653.20 | 3,539 | |
| 10/19/2017 | Value Fund L P Biotechnology | Insider | Buy | 331,916 | $15.84 | $5,257,549.44 | | |
| 9/14/2017 | Ryan Lynch | Insider | Sell | 3,500 | $14.51 | $50,785.00 | 9,500 | |
| 5/12/2016 | Thomas G Auchincloss | Director | Buy | 2,000 | $10.11 | $20,220.00 | 2,000 | |
| 5/11/2016 | Roger D Tung | CEO | Buy | 19,610 | $10.55 | $206,885.50 | 538,965 | |
| 12/16/2015 | Wilfred E Jaeger | Director | Sell | 10,360 | $19.57 | $202,745.20 | | |
| 12/15/2015 | Wilfred E Jaeger | Director | Sell | 54,572 | $20.10 | $1,096,897.20 | | |
| 12/14/2015 | Pauline Mcgowan | VP | Sell | 498 | $20.07 | $9,994.86 | | |
| 12/14/2015 | Wilfred E Jaeger | Director | Sell | 3,922 | $20.09 | $78,792.98 | | |
| 11/9/2015 | Ronald W. Barrett | Director | Sell | 17,699 | $22.27 | $394,156.73 | | |
| 11/2/2015 | Nancy Stuart | COO | Sell | 23,216 | $24.29 | $563,916.64 | 25,004 | |
| 9/18/2015 | Robert Silverman | VP | Sell | 10,000 | $20.00 | $200,000.00 | 10,000 | |
| 9/10/2015 | Wilfred E Jaeger | Director | Sell | 120,000 | $18.22 | $2,186,400.00 | | |
| 8/18/2015 | Wilfred E Jaeger | Director | Sell | 760,000 | $15.81 | $12,015,600.00 | | |
| 8/13/2015 | Wilfred E Jaeger | Director | Sell | 92,215 | $16.75 | $1,544,601.25 | | |
| 8/12/2015 | Wilfred E Jaeger | Director | Sell | 97,785 | $17.49 | $1,710,259.65 | | |
| 6/8/2015 | Robert Silverman | VP | Sell | 5,000 | $16.35 | $81,750.00 | | |
| 3/11/2015 | Nancy Stuart | COO | Sell | 46,430 | $15.00 | $696,450.00 | | |
| 3/11/2015 | Pauline Mcgowan | VP | Sell | 5,973 | $16.00 | $95,568.00 | | |
| 3/10/2015 | Pauline Mcgowan | VP | Sell | 22,122 | $13.90 | $307,495.80 | | |
| 11/18/2014 | Three Arch Management Iv, L.L. | Director | Sell | 250,000 | $12.29 | $3,072,500.00 | | |
| 2/20/2014 | Skyline Venture Partners Quali | Major Shareholder | Buy | 150,000 | $14.00 | $2,100,000.00 | | |
| 2/19/2014 | Life Science Ventures Vi G Tvm | Director | Buy | 89,000 | $14.00 | $1,246,000.00 | | |
| 2/19/2014 | Plc Glaxosmithkline | Major Shareholder | Buy | 35,000 | $14.00 | $490,000.00 | | |
(Data available from 1/1/2013 forward)
Concert Pharmaceuticals (NASDAQ CNCE) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Zacks: Analysts Expect Concert Pharmaceuticals (CNCE) Will Post Quarterly Sales of $20,000.00
www.americanbankingnews.com - May 22 at 2:50 AM |
| Zacks: Analysts Expect Concert Pharmaceuticals (CNCE) to Announce -$0.62 Earnings Per Share
www.americanbankingnews.com - May 20 at 5:14 PM |
| Concert Pharmaceuticals (CNCE) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 14 at 5:31 PM |
 | Concert Pharmaceuticals' (CNCE) CEO Roger Tung on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 6 at 8:54 AM |
| Concert Pharmaceuticals (CNCE) Announces Earnings Results
www.americanbankingnews.com - May 4 at 6:32 PM |
| HC Wainwright Reiterates Buy Rating for Concert Pharmaceuticals (CNCE)
www.americanbankingnews.com - May 4 at 3:17 PM |
 | Edited Transcript of CNCE earnings conference call or presentation 3-May-18 12:30pm GMT
finance.yahoo.com - May 4 at 8:45 AM |
| Concert Pharmaceuticals (CNCE) Upgraded by ValuEngine to Buy
www.americanbankingnews.com - May 3 at 10:43 PM |
| Concert Pharmaceuticals Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 3 at 8:43 AM |
| Concert: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 8:43 AM |
| -$0.61 Earnings Per Share Expected for Concert Pharmaceuticals (CNCE) This Quarter
www.americanbankingnews.com - May 3 at 5:15 AM |
| Zacks Investment Research Downgrades Concert Pharmaceuticals (CNCE) to Hold
www.americanbankingnews.com - May 2 at 10:58 PM |
| Concert Pharmaceuticals (CNCE) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - May 2 at 8:10 PM |
| Concert Pharmaceuticals (CNCE) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 1 at 9:52 PM |
 | BRIEF-Concert Pharmaceuticals Completes Enrollment In Phase 2A Trial Of CTP-543 In Alopecia Areata
www.reuters.com - April 27 at 4:56 PM |
 | Concert Pharmaceuticals to Report First Quarter 2018 Financial Results on May 3, 2018, and Present at Upcoming ...
www.businesswire.com - April 27 at 4:56 PM |
| Wired News – Concert Pharma Enrolled Last Patient in Phase-2a Trial Evaluating CTP-543 in Alopecia Areata
finance.yahoo.com - April 27 at 9:07 AM |
| Concert Pharmaceuticals to Report First Quarter 2018 Financial Results on May 3, 2018, and Present at Upcoming Investor Conferences
finance.yahoo.com - April 26 at 8:40 AM |
| Concert Pharmaceuticals (CNCE) Lowered to Hold at ValuEngine
www.americanbankingnews.com - April 25 at 12:14 PM |
| Concert Pharma completes enrollment in mid-stage study of CTP-543 in autoimmune-related hair loss
seekingalpha.com - April 25 at 8:45 AM |
| Concert Pharmaceuticals Completes Enrollment in Phase 2a Trial of CTP-543 in Alopecia Areata
finance.yahoo.com - April 25 at 8:45 AM |
 | Research Report Identifies Signature Bank,...
www.benzinga.com - April 23 at 8:36 AM |
| Insider Selling: Concert Pharmaceuticals (CNCE) Insider Sells 10,582 Shares of Stock
www.americanbankingnews.com - April 19 at 7:35 PM |
| Concert Pharmaceuticals (CNCE) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 19 at 5:40 PM |
| Concert Pharmaceuticals (CNCE) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 18 at 6:54 PM |
| $20,000.00 in Sales Expected for Concert Pharmaceuticals (CNCE) This Quarter
www.americanbankingnews.com - April 18 at 4:32 AM |
| Concert Pharmaceuticals (CNCE) Expected to Post Earnings of -$0.61 Per Share
www.americanbankingnews.com - April 16 at 3:22 AM |
| Concert Pharmaceuticals (CNCE) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - April 11 at 11:23 PM |
| Concert Pharmaceuticals (CNCE) Earns "Buy" Rating from Mizuho
www.americanbankingnews.com - April 10 at 1:42 PM |
| Concert Pharmaceuticals (CNCE) Coverage Initiated at Mizuho
www.americanbankingnews.com - April 4 at 9:04 PM |
| Concert Pharmaceuticals (CNCE) Raised to Buy at ValuEngine
www.americanbankingnews.com - April 4 at 12:02 AM |
| Concert Pharmaceuticals (CNCE) Cut to C at TheStreet
www.americanbankingnews.com - April 3 at 10:36 AM |
| Analysts Expect Concert Pharmaceuticals Inc (CNCE) Will Post Quarterly Sales of $20,000.00
www.americanbankingnews.com - April 1 at 4:38 AM |
| Analysts Expect Concert Pharmaceuticals Inc (CNCE) to Announce -$0.61 Earnings Per Share
www.americanbankingnews.com - March 30 at 9:04 AM |
| Concert Pharmaceuticals (CNCE) Lifted to "B-" at TheStreet
www.americanbankingnews.com - March 28 at 8:14 PM |
| Concert Pharmaceuticals (CNCE) Downgraded by ValuEngine to Sell
www.americanbankingnews.com - March 28 at 12:58 PM |
| Concert Pharmaceuticals (CNCE) Lowered to Hold at BidaskClub
www.americanbankingnews.com - March 28 at 11:21 AM |
| BidaskClub Lowers Concert Pharmaceuticals (CNCE) to Hold
www.americanbankingnews.com - March 28 at 12:34 AM |
| Concert Pharmaceuticals (CNCE) Upgraded to Hold at ValuEngine
www.americanbankingnews.com - March 25 at 7:32 PM |
| Concert Pharmaceuticals Inc (CNCE) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 25 at 5:32 PM |
| Edited Transcript of CNCE earnings conference call or presentation 1-Mar-18 1:30pm GMT
finance.yahoo.com - March 18 at 8:46 AM |
| Zacks: Brokerages Expect Concert Pharmaceuticals Inc (CNCE) to Post -$0.61 Earnings Per Share
www.americanbankingnews.com - March 13 at 5:18 AM |
| Concert Pharmaceuticals (CNCE) Upgraded to "Buy" by Mizuho
www.americanbankingnews.com - March 9 at 11:24 PM |
| Concert Pharmaceuticals (CNCE) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 8 at 8:48 PM |
| Concert Pharmaceuticals Present at Upcoming Investor Conferences
finance.yahoo.com - March 6 at 8:44 AM |
| Senzar Asset Management LLC Has $7.15 Million Holdings in Concert Pharmaceuticals Inc (CNCE)
www.americanbankingnews.com - March 5 at 3:44 PM |
| Concert Pharmaceuticals' (CNCE) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - March 3 at 6:02 PM |
| 292,010 Shares in Concert Pharmaceuticals Inc (CNCE) Acquired by Bogle Investment Management L P DE
www.americanbankingnews.com - March 3 at 4:52 AM |
| Concert Pharmaceuticals (CNCE) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 2 at 9:02 PM |
| EAM Investors LLC Purchases Shares of 74,232 Concert Pharmaceuticals Inc (CNCE)
www.americanbankingnews.com - March 2 at 1:06 PM |
Concert Pharmaceuticals (NASDAQ:CNCE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Concert Pharmaceuticals (NASDAQ:CNCE) Income Statement, Balance Sheet and Cash Flow Statement
Concert Pharmaceuticals (NASDAQ CNCE) Stock Chart for Wednesday, May, 23, 2018
Loading chart…
